Has Mani Ravee received payments from drug or device companies?

Yes. Drug and device makers reported $4,918 in general payments to Mani Ravee across 202 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mani Ravee did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mani Ravee come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mani Ravee

Pulmonary Disease · Chattanooga, TNNPI 1639226335

Payments from drug & device makers

$4,918in general payments, 2019–2025

Across 202 payments — averaging $24.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$2K
GSK$1K
Actelion Pharmaceuticals US, Inc.$868
Grifols USA, LLC$526
Insmed, Inc.$120
Takeda Pharmaceuticals U.S.A., Inc.$84
plus $308 from 8 others

What the payments were for

Food & beverage$4,78697%
Education$1323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	55	$1,680
GSK	68	$1,332
Actelion Pharmaceuticals US, Inc.	39	$868
Grifols USA, LLC	18	$526
Insmed, Inc.	5	$120
Takeda Pharmaceuticals U.S.A., Inc.	3	$84
Regeneron Healthcare Solutions, Inc.	2	$58
Merck	2	$53
Boehringer Ingelheim	3	$50
Philips North America LLC	2	$40
Mallinckrodt Hospital Products Inc.	2	$39
Resmed Corp	1	$26
Verona Pharma, Inc.	1	$24
Inogen, Inc.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,918 in reported general payments places this provider in the 55th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
UptraviSelexipag	21	$425,902
OpsumitMacitentan	16	$192,638
Prolastin CAlpha-1-Proteinase Inhibitor	11	$101,133
Breztri AerosphereBudesonide/Glycopyr/Formoterol	112	$100,159
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	73	$82,701
Albuterol Sulfate HfaAlbuterol Sulfate	54	$2,120
NovologInsulin Aspart	14	$943
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	11	$290
Atorvastatin Calcium	11	$163
Amlodipine Besylate	23	$124
Lisinopril	14	$49
Hydrochlorothiazide	12	$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit	$868	$618,54137 claims
Grifols USA, LLCProlastin C	$526	$101,13311 claims
AstraZenecaBreztri Aerosphere	$1,680	$100,159112 claims
GSKTrelegy Ellipta	$1,332	$82,70173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Chattanooga

Krishnendu BhadraChattanooga$631K
Michael CzarneckiChattanooga$348K
Carlos BaleeiroChattanooga$265K
Vincent ViscomiChattanooga$28K
Daniel SmithChattanooga$21K
Fabien MaldonadoNashville$2.5M
Aaron MilstoneFranklin$2.4M
John SwisherKnoxville$2.3M
James TolleNashville$2.3M
Lisa LancasterNashville$1.6M

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →